Celine Halioua, founder of the San Francisco-based startup Loyal, has raised $135 million from leading investors to develop canine longevity pills aimed at extending dogs' lifespans by targeting metabolic and hormonal imbalances before they lead to disease. Loyal anticipates receiving its first conditional approval from the U.S. Food and Drug Administration (FDA) next year. Separately, advancements in anti-aging research include the Prometheus Cell Team's development of "Prometheus Cells," which reprogram patients' skin fibroblasts into stem cell-like cells to promote immune balance and tissue repair, with initial clinical trial results expected soon. Additionally, researchers have identified a protein called ReHMGB1 that spreads aging signals through the bloodstream, driving cellular senescence and systemic decline; blocking this protein in mice showed promising results in slowing aging. These developments highlight ongoing efforts in both veterinary and human longevity research.